18 results about "Protein adsorption" patented technology

This invention relates to the field of medical device technology and provides a method for preparing a drug sustained-release coating and a medical device containing the same. The method includes forming a drug sustained-release coating on the surface of the medical device using a drug sustained-release polymer and a drug. The drug sustained-release polymer is a multi-component polymer containing functional groups for anti-protein adsorption, drug sustained-release, and chemical cross-linking. While ensuring the anticoagulant properties and adhesion to the surface of the medical device, the drug sustained-release coating, through the synergistic effect of butyl methacrylate and trimethoxysilyl propyl methacrylate, achieves an initial burst release of less than 20% of the total drug amount and slows down drug release to ensure a drug release cycle in vivo of no less than 21 days. This drug sustained-release coating can release a stable amount of drug to the tissue wall it contacts over a long period, aiming to achieve a long-term therapeutic or preventative effect on diseases such as luminal stenosis.

To provide a protein adsorption inhibitor that can suppress the adsorption of proteins to surfaces such as immunoreaction vessels and measuring instruments to a high degree, while also reducing variability between measurements. [Solution] Formula (1): Z-{O-[(PO) a (EO) b ]-(AO) c -H]} x A protein adsorption inhibitor comprising an alkylene oxide derivative represented by (the definition of the symbols in the formula is as described in the specification), wherein the cloud point of a 1% by mass aqueous solution of the alkylene oxide derivative is 0°C or higher and 30°C or lower.

This invention relates to a hyperbranched polylysine-modified macroporous chromatographic medium, its preparation method, and its application, belonging to the field of chromatographic separation technology. The preparation method includes the following steps: dispersing macroporous polysaccharide microspheres in a solvent to obtain a medium suspension; subsequently adding epichlorohydrin to the medium suspension and mixing thoroughly; adding sodium hydroxide solution to the medium suspension and stirring to obtain an epoxidized macroporous polysaccharide medium; immersing the epoxidized macroporous polysaccharide medium in a hyperbranched polylysine solution and stirring to ensure sufficient diffusion of the hyperbranched polylysine within the microspheres; the hyperbranched polylysine does not contain any hydrophobic groups; adding sodium hydroxide solution and sodium borohydride solution to the system and stirring to obtain the hyperbranched polylysine-modified macroporous chromatographic medium. Compared with existing technologies, this invention utilizes hyperbranched polylysine to modify macroporous chromatographic media, which can significantly improve protein adsorption capacity and adsorption rate.

Disclosed herein is a surfactant additive, ethylenediamine tetrakis(ethoxylate-block-propoxylate) tetrol with 16 ethylene oxide repeat units and 18 propylene oxide repeat units (known by its trade name as Tetronic 90R4) used as a droplet-additive, or to coat DMF driving electrode surfaces which dramatically improves the capability to work with high-protein-content liquids (e.g., whole blood) on digital microfluidic chips. This surfactant prevents protein adsorption and fouling of DMF electrode surfaces to an extent that was heretofore impossible. Specifically, this surfactant allows for the manipulation of droplets of undiluted whole blood for >1 hour per electrode (>1 50 times better than what is possible for any known additive). This improvement in handling high protein content media will revolutionize blood-based diagnostics on digital microfluidic platforms.

A ketoreductase sequence is modified by adding a His tag, an immobilization carrier is a His-Tag protein adsorption magnetic bead, ketoreductase liquid is used as an active component, the modified ketoreductase is fixed on the protein adsorption magnetic bead carrier in a covalent binding manner, and the modified ketoreductase is immobilized on the protein adsorption magnetic bead carrier in a covalent binding manner. The obtained immobilized ketoreductase can be applied to preparation of ezetimibe intermediate ZT-5, and the method can greatly reduce the production cost, improve the traditional defects of difficulty in filtration, easiness in emulsification and the like, and can realize a real enzyme catalysis green and environment-friendly process.

This invention discloses a fluorinated membrane-fused liposome for modifying immune cells to regulate immunity, its preparation method, and its applications, belonging to the field of biomedical technology. This invention synthesizes a series of lipid molecules with different fluorinated chain lengths, including DOPE-F3, DOPE-F5, DOPE-F7, DOPE-F9, DOPE-F11, and DOPE-F13. Fluorinated membrane-fused liposomes are then prepared using these molecules in combination with other lipid components via a thin-film hydration method. These fluorinated membrane-fused liposomes exhibit excellent anti-protein adsorption capacity, efficient membrane fusion properties, and active spleen targeting. Experiments show that these fluorinated membrane-fused liposomes can achieve efficient membrane fusion with immune cells and effectively accumulate in the spleen in vivo, overcoming the shortcomings of traditional liposomes such as easy liver retention and low endocytosis efficiency. This invention has broad application prospects in the field of immunocellular therapy.

This invention belongs to the field of biomedical material preparation technology, specifically relating to a zwitterionic fluoropolymer, its preparation method, and its application in fluorine magnetic resonance imaging and radionuclide delivery. This invention provides a zwitterionic fluoropolymer with a high fluorine content (≥15wt%) and consistent chemical shifts of fluorine atoms, enabling highly sensitive fluorine magnetic resonance imaging. This invention modifies the fluorine-containing fragments to enhance hydrophilicity, introducing a hydrophilic zwitterionic structure near the fluorine atoms. This ensures that even at high polymer concentrations, the fluorine atoms maintain good hydrophilicity, avoiding signal degradation caused by fluorine-fluorine hydrophobic interactions. Furthermore, the zwitterionic structure endows the probe with good water solubility and anti-protein adsorption capabilities, enabling effective delivery of chemotherapeutic drugs and radionuclides. Simultaneously, the probe exhibits good biocompatibility, facilitating detection in deep tissues in vivo.

The application belongs to but is not limited to the technical field of gene synthesis, and discloses a preparation method of a red blood cell membrane coated framework nucleic acid nanogel, which forms NG through base complementary pairing, and realizes the compounding of RBCm and NG by using an Avanti small extruder.SiRNA is combined and cross-linked with TDN through base complementary to form NG, and the TDN provides the first layer of protection for the siRNA, enhances the stability and drug efficacy of the siRNA, and the red blood cell membrane provides the second layer of protection to prevent enzyme degradation and protein adsorption.M@NG combines the bionics and biocompatibility of RBCm and the high drug loading and stability of NG, and has the characteristics of targeted drug delivery, immune escape and the like.The system is suitable for the treatment of various diseases, and expands the application field of RNA interference technology.

This invention relates to a polyamino acid exchange chromatography medium based on end-group immobilization, its preparation method, and its application. The preparation method includes the following steps: dispersing macroporous polysaccharide microspheres in a solvent to obtain a medium suspension; adding epichlorohydrin to the medium suspension and mixing thoroughly; adding sodium hydroxide solution to the medium suspension and stirring to obtain an epoxidized macroporous polysaccharide medium; immersing the epoxidized macroporous polysaccharide medium in an aqueous solution of polyanionic amino acids and stirring to promote the diffusion of polyanionic amino acids within the microspheres; adding sodium hydroxide solution and sodium borohydride solution to the mixture and stirring to obtain the polyamino acid exchange chromatography medium based on end-group immobilization. Compared with existing technologies, this invention utilizes end-group immobilized polyamino acid modification to prepare a macroporous cation exchange chromatography medium, significantly improving the protein adsorption capacity and rate of the chromatography medium.

This application provides a protein adsorption inhibitor that can effectively inhibit protein adsorption onto the surfaces of immunoreaction containers, assay instruments, etc., while reducing inter-assay bias. The protein adsorption inhibitor is characterized by containing the following formula (1): Z-{O-[(PO)] a / (EO) b ]-(AO) c -H]} x (The symbols in the formula are defined as described in the specification) represent alkylene oxide derivatives, and the turbidity point of a 1% by mass aqueous solution of the alkylene oxide derivative is above 0°C and below 30°C.

The application relates to the technical field of biological medicine manufacturing, and discloses a controlled-release type preparation composition for realizing ovary function recovery, which comprises a core active unit, a moisturizing slow-release unit and a plant extract component. The core active unit is an anisotropic core-shell structure microcapsule with asymmetric charge distribution, which is composed of chitosan, polyglutamic acid and an internal compound, and a layer of outwardly radiating carboxyl brush-shaped molecular chain is distributed on the surface of the core active unit. The moisturizing slow-release unit comprises a polymer skeleton formed by rosmarinic acid and hyaluronic acid, and the polymer skeleton internally occludes elemene. The application utilizes a kinetic restriction mechanism to construct an anisotropic surface layer topology, avoids mucus protein adsorption, induces anti-inflammatory immune regulation by physically adapting mucosal receptors, the moisturizing slow-release unit firstly constructs a physical barrier to repair damage, and the core active unit is used to realize component graded controlled release.

This invention discloses a class of dendritic lipopeptide molecules that promote the oral absorption of macromolecular drugs, their preparation method, and applications. The dendritic lipopeptide molecules are formed by combining a hydrophilic head and a hydrophobic tail. The hydrophilic head consists of lysine and glutamic acid linked by amide bonds, while the hydrophobic tail is composed of organic carbon chains or fluorinated chains. The oral absorption enhancer used in this invention exhibits amphoteric characteristics, possessing excellent anti-protein adsorption capabilities, superior mucus penetration and small intestinal permeability, and good biocompatibility due to its amino acid element construction. The oral absorption enhancer used in this invention can cross multiple barriers, including the mucus layer and intestinal epithelial cells, without opening tight junctions, facilitating efficient and safe oral encapsulation and delivery of proteins.

The application discloses an enhanced anti-coagulation and anti-bacterial hemodialysis hollow fiber membrane and a preparation method thereof, and belongs to the technical field of medical membrane materials. The acid activation-polydopamine coating-sulfonated grafting modification of halloysite nanotubes is carried out in the application, so that the surface sulfonic acid group density of the halloysite nanotubes reaches 0.8-2.1 mmol / g, and the Zeta potential is less than or equal to-30 mV. The modified halloysite is dispersed in a polar aprotic solvent in advance, is incorporated into a polymer matrix after ultrasonic treatment, is filtered through a sintering filter element with a diameter of less than or equal to 5 mu m, is defoamed, is spun by using a dry spraying-wet spinning method, and is prepared into a finished product through coagulation, rinsing and drying. The application constructs a heparin-like negative charge layer, so that the activated partial thromboplastin time (APTT) is greater than or equal to 55 s, platelet adhesion and protein adsorption are significantly inhibited, and the application has a broad-spectrum antibacterial performance. The rigid halloysite induces the formation of through channels, so that the pain point that a high-flux membrane is easy to damage red blood cells is solved, the process is stable, and the application is suitable for industrial production.

The application relates to the technical field of biological vaccines, in particular to a zinc-aluminum composite adjuvant and a preparation method thereof. The preparation method comprises the following steps: mixing a zinc salt solution and a specific complexing agent solution, adjusting pH, and forming a mixed solution A; under stirring, simultaneously adding an aluminum salt solution and a mixed alkali solution containing a phosphate and a hydroxide into the mixed solution A, controlling the pH of a reaction system in a range of 6.5-7.5, and obtaining a zinc-aluminum composite suspension after reaction; and finally, washing and sterilizing to obtain the zinc-aluminum composite adjuvant. The complexing agent is preferably a compound of L-histidine and carnosine succinamide. The zinc-aluminum composite particles with uniform structure and high stability are prepared through step-by-step coprecipitation and synergistic control of the preferred organic ligand, the problems of easy agglomeration and large batch difference of the traditional adjuvant in the terminal sterilization process are effectively solved, and the stability and protein adsorption capacity of the adjuvant are significantly improved.

An apparatus for refining proteins or other biomolecules in biological compositions, such as for separation of proteins from milk, whey, blood plasma, fermentation broth, or similar.

The application belongs to the technical field of medicine, and particularly relates to a tumor microenvironment responsive polymer-drug conjugate as well as a preparation method and application thereof. The polymer-drug conjugate has a structure as shown in formula (1), wherein R1 is a hydrophilic group with anti-protein adsorption capacity; R2 is a microenvironment responsive group; R3 is a linker which is connected with R1 and R2 through a carbon-carbon bond, a phosphorus ester bond, an ester bond, an amide bond, an urethane bond and an ether bond respectively, and is connected with R4 through various chemical bonds formed through bio-orthogonal chemical reaction; R4 is an anti-tumor drug group with a-linker-Drug structure, and linker is a group with at least one of reduction, active oxygen, pH and enzyme responsiveness. The polymer-drug conjugate obtained in this way can be enriched and penetrated in a large amount at a tumor tissue site, and through the breaking of the responsive linker bond, the drug is released at the tumor tissue site, thereby producing a good tumor treatment effect.

This invention discloses an injectable shear-responsive superlubricating hydrogel and its preparation method. The preparation method involves dissolving a zwitterionic monomer and hyaluronic acid in a liposome solution, adding a crosslinking agent, initiator, and accelerator, and crosslinking at room temperature to obtain the superlubricating hydrogel. Pre-adding a drug to the liposome solution allows for drug loading. The zwitterionic monomer is selected from carboxyl or sulfobetaine, whose molecular chains have equal amounts of positive and negative charges that strongly interact with water molecules, constructing a dense hydration layer. Hyaluronic acid uniformly binds the liposomes within the gel network through electrostatic interactions. Under external shear stress, the hydrogel undergoes structural rearrangement, exposing the internal liposomes to the sliding surface to form a lipid boundary layer, which, in conjunction with the zwitterionic hydration layer, achieves stable and durable boundary lubrication. This hydrogel exhibits an extremely low coefficient of friction, while also possessing excellent self-healing properties, injectability, anti-protein adsorption characteristics, and drug sustained-release capability.

This application provides a method for preparing an anti-biofouling ultrafiltration membrane. By copolymerizing cellulose acetate and dextran-40 and optimizing their composition and ratio, the pore size distribution range of the ultrafiltration membrane can be controlled, achieving more precise pore size control. Dextran-40 has good anti-protein adsorption properties, while cellulose acetate has certain hydrophilic properties. The copolymerized product may have better antifouling properties, reducing protein adsorption and membrane adhesion, and extending the service life of the ultrafiltration membrane. This solves the technical problems of poor antifouling performance of existing ultrafiltration membranes, which leads to a decrease in membrane flux, and poor adhesion of chitosan to polyethersulfone, which easily dissolves and causes the failure of antifouling ability. By fixing the composite material of silver nanoparticles and chitosan onto the ultrafiltration membrane by inkjet printing, an antibacterial layer can be formed, enhancing the antibacterial properties of the ultrafiltration membrane and reducing the adhesion and reproduction of microorganisms.